AzTrials
AzTrials

GlaucomaBANMOPNCT07763288

Prevalence of Glaucoma and Normative Data of Ocular Biometry in Elderly Population in Bangkok

An observational study of Glaucoma and Glaucoma, Open-Angle, run by Siriraj Hospital at 1 site in Thailand.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The BANMOP eye study is an ophthalmic subproject of the Bangkoknoi Model Project (BANMOP), a community-based initiative integrating electronic health databases with population surveys to sup-port context-specific health promotion and prevention strategies. Read more about this study

Who is it for?
Ages 50 years and olderHealthy volunteers can take part
Conditions the study is for
Glaucoma, Glaucoma, Open-Angle, Glaucoma, Suspect
How many people
1,470 participants
Where
1 siteThailand
Study dates
1 Apr 2024to 29 Jan 2025
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The Bangkoknoi Model Eye Project is a population-based cohort study conducted in 42 communities within the Bangkoknoi district, a suburban area of Bangkok, Thailand. Using a convenience sampling approach, people aged ≥50 years from the 42 communities were invited to participate.

Who may be able to join

  • people aged ≥50 years from the 42 communities of Bangkoknoi district of Bangkok

Who cannot join

  • Individual who is unable to visit the mobile unit for eye examination.

Trial locations and contacts

1 site in 1 country.

Thailand1 site
  • Naris Kitnarong

    Nonthaburi, 11000

Other trials in Thailand

About this study

Official title: Prevalence of Glaucoma and Normative Data of Ocular Biometry in Elderly Population in Bangkok: The Bangkoknoi Model Project (BANMOP)

The BANMOP eye study is an ophthalmic subproject of the Bangkoknoi Model Project (BANMOP), a community-based initiative integrating electronic health databases with population surveys to sup-port context-specific health promotion and prevention strategies. A total of 1,470 participants aged ≥50 years were recruited from community clusters in the Bangkoknoi district between April and Au-gust 2024. All participants underwent standardized ophthalmic examinations including slit-lamp bio-microscopy, noncontact tonometry (NCT), fundus photography, anterior segment optical coherence tomography (AS-OCT), and spectral-domain OCT (Spectralis, glaucoma module premium edition). Individuals suspected of glaucoma based on optic nerve head findings, intraocular pressure, or screen-ing results were referred for comprehensive evaluation by glaucoma specialists for definitive diagno-sis and classification.

Read the detailed description

Study Design and Population The Bangkoknoi Model Eye Project is a population-based cohort study conducted in 42 communities within the Bangkoknoi district, a suburban area of Bangkok, Thailand. Ethical approval was obtained from the Institutional Review Board of the Siriraj Hospital Faculty of Medicine, Mahidol University (COA No. SI 077/2024) according to the principles of the Declaration of Helsinki. The study was prospectively registered to Thai Clinical trial registration on July 19, 2023.

The project was partially funded by the National Health Security Office (NHSO), the Siriraj Social Responsibility Fund, and the Siriraj Research Development Fund (grant number R016733016), Siriraj Hospital Faculty of Medicine, Mahidol University.

The BANMOP community network management team, consisting of researchers and local coordinators, organized meetings with community leaders to facilitate the implementation of the study. The study was communicated through community leaders and the Bangkoknoi District Bureau to encourage voluntary participation. Using a convenience sampling approach, people aged ≥50 years from the 42 communities were invited to participate.

All examinations were performed using a mobile ophthalmic survey unit established at each community site, including community centers and schools, between April and August 2024.

Medical and Ocular History Participants were interviewed to obtain medical and ocular history, including previous eye diseases, ocular trauma, previous or current ophthalmic treatments or surgeries, and systemic comorbidities such as diabetes mellitus, hypertension, and dyslipidemia.

Uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA) were measured using standardized protocols. Automated refraction was performed using an autorefractometer (AR-610; Nidek Co., Ltd., Tokyo, Japan). Blindness was defined as a BCVA worse than logMAR 1.3 (Snellen equivalent <3/60).

Intraocular Pressure and Posterior Segment Imaging Intraocular pressure (IOP) was measured by experienced technicians using a noncontact pneumotonometer (CT-60 computerized tonometer; Topcon Ltd., Tokyo, Japan). At least three measurements were obtained for each eye and the mean value was used for analysis.

Color fundus photographs of the macula and optic disc were obtained using a fundus camera (CR6-45NM; Canon Inc., Tokyo, Japan). Spectral-domain optical coherence tomography (SD-OCT; Heidelberg Engineering, Germany) was performed to image the optic nerve head and macula using standard acquisition protocols. Because additional examinations, including Goldmann applanation tonometry (GAT), glaucoma module premium edition OCT (GMPE), and dark-room anterior segment OCT (AS-OCT), were not feasible for all participants within the constraints of a community-based mobile survey, these investigations were performed in a subset of participants using a convenience sampling approach. Comprehensive slit-lamp biomicroscopy was performed by ophthalmologists. Goldmann applanation tonometry (GAT) was performed by glaucoma specialists in the selected subset of participants.

Anterior Segment Assessment The depth of the anterior chamber was initially assessed using the van Herick method. Eyes with a peripheral anterior chamber depth less than one-quarter of the corneal thickness underwent gonioscopy, performed by experienced ophthalmologists using a 4-mirror goniolens. Anterior segment optical coherence tomography (AS-OCT) was performed under standard room lighting conditions to evaluate anterior chamber angle parameters, anterior chamber depth (ACD), central corneal thickness (CCT) and lens thickness (LT). Dark-room AS-OCT imaging was also performed in a subset of participants selected using convenience sampling.

Glaucoma Definition and Classification Glaucoma suspects were defined as individuals with suspicious glaucomatous features of the optic nerve head, including a cup-to-disc ratio >0.6, inter-eye asymmetry >0.2, localized neuroretinal rim loss, defects of the retinal nerve fiber layer, and/or IOP >21 mmHg (confirmed by GAT) with or without the corresponding SD-OCT abnormalities. All suspected glaucoma patients were referred to Siriraj Hospital for further evaluation, including Humphrey visual field (HVF) testing (SITA 24-2) and comprehensive examination by glaucoma specialists for definitive diagnosis. Glaucoma was defined by the presence of glaucomatous optic neuropathy (structural evidence) with corresponding glaucomatous defects of the visual field (functional evidence), and/or elevated IOP >21 mmHg measured by GAT. Glaucoma was classified as primary open-angle glaucoma (POAG), normal tension glaucoma (NTG), primary angle-closure glaucoma (PACG) and secondary glaucoma. Gonioscopy was performed in all cases of glaucoma, suspected glaucoma, and cases with angle-closure using the modified Shaffer grading system. Open angle glaucoma was defined by an open anterior chamber angle on gonioscopy.

Normal-tension glaucoma (NTG) was defined as glaucomatous optic neuropathy in eyes with open angles and untreated IOP <21 mmHg. Ocular hypertension (OHT) was defined as IOP >21 mmHg without structural or functional glaucomatous damage.

Primary angle-closure disease (PACD) was defined as an occludable or closed anterior chamber angle, characterized by invisibility of ≥180° of the posterior trabecular meshwork on gonioscopy. PACD was further classified into primary angle-closure suspect (PACS), primary angle closure (PAC), and primary angle-closure glaucoma (PACG).

Secondary glaucoma was defined as glaucoma with an identifiable underlying cause. Pre-existing glaucoma cases were confirmed based on current glaucoma medications or review of medical records at Siriraj Hospital.

Statistical analysis was performed using SPSS for Windows, version 29.0 (SPSS Inc., Chicago, Illinois, USA). Continuous variables were summarized as mean ± standard deviation (SD), while categorical variables were presented as frequencies and percentages. Comparisons of proportions between groups were performed using the chi-square test or Fisher's exact test, as appropriate. Logistic regression models were used to evaluate associations between the presence of glaucoma and potential risk factors, including continuous variables (e.g., intraocular pressure) and categorical variables (e.g., unilateral blindness). The agreement between continuous variables were compared using intraclass correlation coefficient. All P values are 2-sided, and statistical significance was defined as P < 0.05.

Keywords
Glaucoma, prevalence,, epidemiological study, primary angle-closure, primary open angle glaucoma, optical coherence tomography, Asian, thailand
Medical subject headings
Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension, Glaucoma, Angle-Closure, Cataract, Blindness

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the prevalence of glaucoma and its subtypes

    the prevalence of glaucoma and its subtypes in individuals 50 years of age and older including primary angle-closure diseases, primary open angle glaucoma, glaucoma suspect

    Measured: 5 months between April 1st to August 31st, 2024

  2. characterize the spectrum of primary angle-closure diseases (PACD)

    characterize the spectrum of PACD according to ISGEO definitions, identify eyes at high risk of angle-closure disease

    Measured: 5 months between April 1st to August 31st, 2024

Secondary outcomes (1)
  1. Establish baseline ocular biometric and optical coherence tomography (OCT)-derived parameters in this population.

    establish baseline ocular biometric and OCT-derived parameters in this population including Spectral-domain optical coherence tomography (SD-OCT; Heidelberg Engineering, Germany) to image the optic nerve head and macula using standard acquisition protocols. Because additional examinations, including Goldmann applanation tonometry (GAT), glaucoma module premium edition OCT (GMPE), and dark-room anterior segment OCT (AS-OCT)

    Measured: 5 months between April 1st to August 31st, 2024

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2026
  2. Study start1 Apr 2024
  3. Primary completion31 Aug 2024
  4. Study completion29 Jan 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrolment
1,470 participants (actual)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT07763288
Sponsor's protocol ID
SI 077/2024
Other IDs
R016733016
Acronym
BANMOP
Status last verified
Aug 2026
First submitted
8 Aug 2026
Last updated
13 Aug 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: We did collect individual data of AS OCT, OCT of the disc and macula, demographic data which could be shared in reasonable purposes.

Publications

  • Kitnarong N, Muangpaisan W, Kaweewongprasert P, Luerithiphong S, Apinuntavech S, Manaboriboon B, Talungchit P, Chainuvati S, Srinonprasert V, Kade S, Supamanee K, Assantachai P, Watanapa P. Electronic health databases and surveys for community-specific health promotion, prevention, and interventions: the Bangkoknoi Model Project (BANMOP). BMC Health Serv Res. 2025 May 10;25(1):678. doi: 10.1186/s12913-025-12837-z.

    PubMed 40349067
  • Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002 Feb;86(2):238-42. doi: 10.1136/bjo.86.2.238.

    PubMed 11815354
  • Bourne RR, Sukudom P, Foster PJ, Tantisevi V, Jitapunkul S, Lee PS, Johnson GJ, Rojanapongpun P. Prevalence of glaucoma in Thailand: a population based survey in Rom Klao District, Bangkok. Br J Ophthalmol. 2003 Sep;87(9):1069-74. doi: 10.1136/bjo.87.9.1069.

    PubMed 12928267
  • Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y; Tajimi Study Group, Japan Glaucoma Society. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005 Oct;112(10):1661-9. doi: 10.1016/j.ophtha.2005.05.012.

    PubMed 16111758
  • Foster PJ, Oen FT, Machin D, Ng TP, Devereux JG, Johnson GJ, Khaw PT, Seah SK. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol. 2000 Aug;118(8):1105-11. doi: 10.1001/archopht.118.8.1105.

    PubMed 10922206

Questions about this trial

What is this clinical trial studying?

An observational study of Glaucoma and Glaucoma, Open-Angle, run by Siriraj Hospital at 1 site in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the prevalence of glaucoma and its subtypes (time frame: 5 months between April 1st to August 31st, 2024). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07763288, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in